Boehringer Ingelheim GmbH

In 2.5 years, production of innovative thrombolytics for infarction and cerebral accident treatment will be launched in the Moscow Region. The agreement on the localization of the full production cycle of modern medications was signed between Boehringer Ingelheim GmbH and NPO Petrovax Pharm on June 9 in the Chamber of Commerce and Industry of the RF at the meeting devoted to the development of high technology healthcare in the sphere of cardiovascular diseases in Russia.

10 June 2016
www.newizv.ru
Investor

Investor profile

Boehringer Ingelheim GmbH

Ingelheim, Germany

Company's website: www.boehringer-ingelheim.com

T: +49 6132770

Private company

Contact: Dr Andreas Barner, Chairman of the Board and Corporate Board Divisions Human Resources, Research & Development and Medicine

Boehringer Ingelheim is one of the world's largest pharmaceutical firms. Since it was launched in 1885, it has been committed to researching, manufacturing and marketing innovative therapeutic products for human and veterinary medicine.